Urinary detection of rapid-acting insulin analogs in healthy humans

被引:15
|
作者
Judak, Peter [1 ]
Coppieters, Gilles [1 ]
Lapauw, Bruno [2 ]
Van Eenoo, Peter [1 ]
Deventer, Koen [1 ]
机构
[1] Univ Ghent, Dept Diagnost Sci, Doping Control Lab, Technol Pk 30, B-9052 Zwijnaarde, Belgium
[2] Ghent Univ Hosp, Dept Endocrinol, Ghent, Belgium
关键词
elimination time; healthy volunteers; insulins; mass spectrometry; urine; LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY;
D O I
10.1002/dta.2817
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Human insulin and its synthetic analogs are considered as life-saving drugs for people suffering from diabetes mellitus. Next to the therapeutic use, scientific and non-scientific literature (e.g. bodybuilding forums; antidoping intelligence and investigation reports) indicate that these prohibited substances are used as performance enhancing agents. In the present report, the development and validation of a sensitive analytical strategy is described for the urinary detection of three rapid-acting insulin analogs (Lispro, Aspart, Glulisine). The method is based on sample purification by the combination of ultrafiltration and immunoaffinity purification and subsequent analysis by nano-flow liquid chromatography coupled to high resolution mass spectrometry. Next to the results on different validation parameters (LOD: 10 pg/mL; recovery: 25-48%; matrix effect: -3-(-8) %), data on urinary elimination times, which were obtained in the frame of an administration study with the participation of healthy volunteers, are presented. The determined detection windows (9 hours) are expected to help to evaluate current routine analytical methods and aim to aid doping authorities to set appropriate target windows for efficient testing.
引用
收藏
页码:1629 / 1635
页数:7
相关论文
共 50 条
  • [1] Rapid-Acting Insulin Analogs
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2009, 51 (1327): : 98 - 98
  • [2] Subcutaneous Rapid-acting Insulin Analogs for Diabetic Ketoacidosis
    Chow, Lillian
    Valesky, Walter
    ACADEMIC EMERGENCY MEDICINE, 2021, 28 (06) : 700 - 702
  • [3] Safety of Rapid-Acting Insulin Analogs Versus Regular Human Insulin
    Kitabchi, Abbas E.
    Gosmanov, Aidar R.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2012, 344 (02): : 136 - 141
  • [4] Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review
    Fordan, Steve
    Raskin, Philip
    VASCULAR HEALTH AND RISK MANAGEMENT, 2009, 5 : 225 - 231
  • [5] Rapid-acting Insulin Analogs Imitating Physiology even better and assisting the Patients
    不详
    DIABETES STOFFWECHSEL UND HERZ, 2020, 29 (05): : 313 - 313
  • [6] CONCENTRATED RAPID-ACTING INSULIN PREPARATIONS
    Handeslman, Yehuda
    ENDOCRINE PRACTICE, 2017, 23 : 18 - 23
  • [7] Insulin glulisine (Apidra):: A new rapid-acting insulin
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2006, 48 (1233): : 33 - 34
  • [8] Insulin aspart: A new rapid-acting insulin analog
    Setter, SM
    Corbett, CF
    Campbell, RK
    White, JR
    ANNALS OF PHARMACOTHERAPY, 2000, 34 (12) : 1423 - 1431
  • [9] Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers
    Kaku, K
    Matsuda, M
    Urae, A
    Irie, S
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2000, 49 (2-3) : 119 - 126
  • [10] Regular insulin is as effective as rapid-acting insulin analogs in combination with glargine insulin in type 1 diabetic patients
    Ampudia-Blasco, FJ
    Girbés, J
    Sanz, J
    Pedro, T
    Martínez, S
    Catalá, M
    Carmena, R
    DIABETOLOGIA, 2005, 48 : A92 - A92